Treace Medical Concepts (Treace Medical Concepts) EBIT : $-49.6 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Treace Medical Concepts EBIT?

Treace Medical Concepts's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-17.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-49.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Treace Medical Concepts's annualized ROC % for the quarter that ended in Mar. 2024 was -76.84%. Treace Medical Concepts's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -108.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Treace Medical Concepts's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -15.17%.

Treace Medical Concepts EBIT Historical Data

The historical data trend for Treace Medical Concepts's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Treace Medical Concepts EBIT Chart

Treace Medical Concepts Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-3.42

0.86

-16.49

-38.42

-44.36

Treace Medical Concepts Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial													-12.17	-10.99	-16.23	-4.98	-17.36

Competitive Comparison of Treace Medical Concepts's EBIT

For the Medical Devices subindustry, Treace Medical Concepts's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Treace Medical Concepts's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Treace Medical Concepts's EV-to-EBIT falls into.

Treace Medical Concepts EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.6 Mil.

Treace Medical Concepts (NAS:TMCI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Treace Medical Concepts's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-75.872 * ( 1 - 0% )	/	( (98.997	+	98.491)	/ 2 )
=	-75.872	/	98.744
=	-76.84 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	251.907	-	29.712	-	( 123.198	-	max(0, 45.033	-	198.359	+	123.198	))
=	98.997

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	242.726	-	34.229	-	( 110.006	-	max(0, 47.049	-	187.397	+	110.006	))
=	98.491

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Treace Medical Concepts's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-69.436	/	( ( (31.562 + max(31.532, 0))	+	(33.581 + max(31.206, 0)) )	/	2 )
=	-69.436	/	( ( 63.094	+	64.787 )	/	2 )
=	-69.436	/	63.9405
=	-108.59 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(38.063	+	29.245	+	7.853)	-	(29.712	+	0	+	13.917)
=	31.532

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(30.083	+	35.86	+	11.448)	-	(34.229	+	0	+	11.956)
=	31.206

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Treace Medical Concepts's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-49.55	/	326.575
	=	-15.17 %

Treace Medical Concepts EBIT Related Terms

Thank you for viewing the detailed overview of Treace Medical Concepts's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Treace Medical Concepts (Treace Medical Concepts) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Treace Medical Concepts Inc (NAS:TMCI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Palmetto Park Place, Ponte Vedra, FL, USA, 32081

Website

https://www.treace.com

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.

Executives

F Barry Bays	director
Betsy Hanna	director	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE RD #150, PONTE VEDRA BEACH FL 32081
Deepti Jain	director	3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sean F. Scanlan	officer: See Remarks	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
James T Treace	director	117 BRISTOL PLACE, PONTE VEDRA BEACH FL 32082
Richard W Mott	director	1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Thomas E Timbie	director
Daniel E. Owens	officer: Chief HR Officer	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Scot Michael Elder	officer: *See "Remarks"	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Mark Hair	officer: Chief Financial Officer	C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Aaron Berutti	officer: Sr. VP, Sales	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
John T. Treace	director, 10 percent owner, officer: Chief Executive Officer	C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Lance A Berry	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
Jane E Kiernan	director	525 W ROSCOE, CHICAGO IL 60657
John R Treace	director	5677 AIRLINE RD, ARLINGTON VA 38002